Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Price

Structure Therapeutics Inc. American Depositary Shares Price

NYSE·CLOSED
21.73
​
Market closed

Structure Therapeutics Inc. American Depositary Shares stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Structure Therapeutics Inc. American Depositary Shares business model & stock analysis

Structure Therapeutics Inc. develops oral small molecule therapeutics for chronic diseases, with its lead product GSBR-1290 in phase 2 trials for obesity and related conditions. The company also has ACCG-2671 and ACCG-3535 in phase 1 trials for obesity, targeting amylin receptors, and ANPA-0073 for APJ receptor agonism. LTSE-2578, an antagonist for idiopathic pulmonary fibrosis, is in development, alongside GIPR program candidates for obesity treatment through GLP-1R/GIPR modulation. The company focuses on clinical-stage biopharmaceutical products for unmet medical needs, targeting obesity, fibrosis, and related conditions. Its pipeline includes multiple phase 1 and phase 2 programs, with GSBR-1290 being the most advanced candidate. The products are developed for potential commercialization in the United States, targeting patients with chronic diseases requiring novel therapeutic options. Structure Therapeutics generates revenue through the development and potential future commercialization of its drug candidates. The company's products are designed to address conditions like obesity, idiopathic pulmonary fibrosis, and related metabolic disorders, with clinical trials progressing toward regulatory approval. The focus remains on advancing its pipeline toward market entry.

Frequently asked questions about Structure Therapeutics Inc. American Depositary Shares

23 analysts currently rate the Structure Therapeutics Inc. American Depositary Shares stock: 21 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Structure Therapeutics Inc. American Depositary Shares to generate revenue of 38.46 M USD and earnings per share of -2.00 USD.

Converted at the current exchange rate, the Structure Therapeutics Inc. American Depositary Shares share trades at 19.42 EUR (21.73 USD).

The expected revenue of Structure Therapeutics Inc. American Depositary Shares is 38.46 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Structure Therapeutics Inc. American Depositary Shares is -118.38 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Structure Therapeutics Inc. American Depositary Shares is currently -10.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Structure Therapeutics Inc. American Depositary Shares stock.

The price-to-sales ratio (P/S) of Structure Therapeutics Inc. American Depositary Shares is currently 33.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Structure Therapeutics Inc. American Depositary Shares stock.

The Eulerpool Quality Score for Structure Therapeutics Inc. American Depositary Shares is 3/10.

The ISIN of Structure Therapeutics Inc. American Depositary Shares is US86366E1064. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Structure Therapeutics Inc. American Depositary Shares is GPCR. The ticker symbol is used to trade Structure Therapeutics Inc. American Depositary Shares shares on the stock exchange.

Fair ValueTerminal
18.91 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 3, 2023
ISIN
US86366E1064
Market capitalization
1.54 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-10.87
P/Ee 2027
-8.44
P/Ee 2028
-10.43
P/Ee 2029
-422.29
P/Ee 2030
12.51
P/S
P/Se
33.45
EV/EBIT
—
P/B Ratio
1.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-9.29 %
Last updated Nov 11, 2026, 3:54 PM

Structure Therapeutics Inc. American Depositary Shares Peer Group

All fundamentals and in-depth analysis of Structure Therapeutics Inc. American Depositary Shares

Our stock analysis for Structure Therapeutics Inc. American Depositary Shares stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Structure Therapeutics Inc. American Depositary Shares. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.